The administration of human epidermal growth factor receptor 2 (HER2)-specific CAR T-cells led to regression or even elimination of the colorectal cancer xenograft and protection of relapse from rechallenged colon cancer tissue in the PDX model [95]. Here, ERBB2 is linked to colorectal cancer.